4-P-PDOT
4-P-PDOT 性质
| 熔点 | 166 °C |
|---|---|
| 沸点 | 480.1±45.0 °C(Predicted) |
| 密度 | 1.11±0.1 g/cm3(Predicted) |
| 储存条件 | room temp |
| 溶解度 | 溶于 DMSO > 10 mM |
| 酸度系数(pKa) | 15.87±0.40(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
4-P-PDOT 用途与合成方法
MT2 receptor
In CHO-mt1 cells the amidotetraline 4-P-PDOT (10 mM) has no effect on forskolin-stimulated cyclic AMP levels, either alone, or in the presence of Melatonin. In contrast, in CHO-MT2 cells, 4-P-PDOT is an agonist, producing a concentration-dependent inhibition of forskolin stimulated cyclic AMP, with a pEC 50 value of 8.72 and intrinsic activity of 0.86.
Cell Viability Assay
| Cell Line: | HT-29 and HeLa cells. |
| Concentration: | 30 min. |
| Incubation Time: | 50 µM. |
| Result: | Produced a negligible effect on cell viability induced by melatonin. |
4-P-PDOT (0.5-1.0 mg/kg; intravenous injection; klotho mutant mice) treatment significantly reverses antioxidant effects mediated by Melatonin. And significantly reverses the changes in the levels of these GSH-related parameters. 4-P-PDOT treatment significantly reverses the memory function of Melatonin-treated klotho mutant mice. 4-P-PDOT also counteracts Melatonin-mediated attenuation in response to the decreases in phospho-ERK expression, Nrf2 nuclear translocation, Nrf2 DNA-binding activity, and GCL mRNA expression in the hippocampi of klotho mutant mice.
| Animal Model: | Klotho mutant mice treatment with Melatonin |
| Dosage: | 0.5 mg/kg or 1.0 mg/kg |
| Administration: | Intravenous injection |
| Result: | Significantly reversed antioxidant effects mediated by Melatonin. Significantly reversed the changes in the levels of these GSH-related parameters. Significantly reversed the memory function of Melatonin-treated klotho mutant mice. |
4-P-PDOT 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-100609 | 4-P-PDOT | 134865-74-0 | 5mg | 900 |
| 2024-11-08 | HY-100609 | 4-P-PDOT | 134865-74-0 | 10mM * 1mLin DMSO | 990 |
